65,437 trials
Opioid-use Disorder · Medication Assisted Treatment · Chronic Pain
Primary: Retention on Buprenorphine Treatment According to TimeLine Follow-Back - 3-months — 81.1; 75.4 days
Neuropathic Pain · Chronic Pain · Pain
Primary: Change in Neuropathic Pain Symptom Inventory (NPSI) — 47.6; 41; 48.7; 41.5 score on a scale
Physical Inactivity
Primary: Total Step Count (Average Steps/Day) — 5648.91; 3809.62 Steps/day — p=<0.001
Castration-Resistant Prostate Carcinoma · Metastatic Prostate Carcinoma · Stage IVB Prostate Cancer AJCC v8
Primary: Patients Reporting Adverse Reactions — 0 Participants
Substance-Related Disorders · Underage Drinking · Drug Use
Primary: Frequency of Parent-child Conversations on Substances — 87; 32; 29; 20 Participants — p=<0.001
COVID · Severe Acute Respiratory Syndrome · Sars-CoV2
Primary: To Evaluate the Proportion of Subjects Alive and Free of Respiratory Failure and Free of the Need for Continued Renal Replacement Therapy (RRT) on Day 28 (as Per…
Breast Cancer · Prostate Cancer · Hematologic Malignancy
Primary: Change in Fatigue Assessed With Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form (SF) Fatigue 4a — 2.18; 2.03; 1.70; 1.58 score on a scale
Urothelial Carcinoma · Urothelial Cancer · Lung Neoplasms
Primary: Phase I: Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of EP0057 (CLRX101) in Participants With Refractory Cancers. — 12 mg/m^2
Hyperkalaemia · Heart Failure With Reduced Ejection Fraction
Primary: Participants Who Achieved Response, Defined as Serum Potassium (sK+) Within 3.5 to 5.0 mEq/L, Spironolactone Greater Than or Equal to 25 mg Daily, no Rescue Therapy for…
Myofascial Dysfunction
Primary: T1 Rho MRI Relaxation Time of Shoulder External Rotator (Milliseconds) — 29.09; 27.15 milliseconds
Bradycardia
Primary: Complication-Free Rate — 93.3 percentage of participants — p=<0.001
Affect · Bereavement · Emotions
Primary: Self-reported Negative Affect — 1.88; 1.91; 1.70; 1.89 score on a scale — p=0.053
Visual Acuity
Primary: HLHC Binocular logMAR Visual Acuities — -0.088; -0.018; 0.087 logMAR
Cerebral Palsy, Spastic
Primary: Change in Muscle Size Parameter — 3.7; 1.6; 1.4; 0.1 milliliters — p=<0.01
Diabetes Mellitus, Type 2 · Peripheral Arterial Disease
Primary: Change in Maximum Walking Distance on a Constant Load Treadmill Test — 1.21; 1.08 Ratio of maximum walking distance — p=0.0004